THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
Phase of Trial: Phase IV
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Dasabuvir (Primary) ; Elbasvir/grazoprevir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PRIORITIZE
- 03 Feb 2017 Planned number of patients changed from 3750 to 2670.
- 10 Aug 2016 Planned primary completion date changed from 1 Feb 2021 to 1 Aug 2020.
- 07 Jul 2016 New trial record